Want to see MRAI full AI Analyst Report?
Marpai (MRAI) AI Stock Analysis
Marpai
(Other OTC:MRAI)
The overall score reflects very weak financial performance and ongoing cash burn as the dominant risk, partially offset by strong recent price momentum and supportive corporate actions that improve near-term liquidity but do not yet resolve structural profitability and balance sheet issues.
Marpai (MRAI) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $79.39M
- Dividend Yield
- ―
- Average Volume (3M)
- 49.36K
- Price to Earnings (P/E)
- -3.8
- Beta (1Y)
- -0.26
- Revenue Growth
- -29.73%
- EPS Growth
- 11.01%
- Country
- US
- Employees
- 107
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Plans
Marpai Business Overview & Revenue Model
Company Description
Marpai, Inc. operates as a technology-driven healthcare payer, concentrating its efforts on the self-insured employer market within the United States and Israel. The firm provides a comprehensive suite of supplementary services, which includes managi...
Marpai Earnings Call Summary
The earnings call highlighted significant operational improvements and strategic initiatives like cost reduction and new client acquisitions. However, the notable decline in net revenues and ongoing operating losses temper these achievements.
Q3-2025 Updates
Positive Updates
Negative Updates
Company Guidance
In the third quarter of 2025, Marpai reported net revenues of $4 million, representing a 42% decrease compared to the same period in the previous year. Despite this drop in revenue, operating expenses improved by 24%, amounting to $3.9 million. The operating loss narrowed by 2% to $3.5 million, and the net loss reduced by 2% to $3 million. The loss per share improved by $0.10, reaching $0.20. The company emphasized its strategic initiatives to bolster financial stability, including a $3.9 million private investment in public equity. This capital raise is anticipated to support the final stages of their high-growth turnaround plan. Furthermore, Marpai is consolidating claims processing into a single advanced operating system, which is expected to generate substantial cost savings and accelerate profitability.
Marpai Financial Statement Overview
Summary
Revenue is shrinking sharply, gross margin has collapsed to near zero, losses and cash burn remain large, and equity has turned deeply negative despite only modest improvement in recent loss levels.
Income Statement
8Very NegativeBalance Sheet
5Very NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.64M | 18.10M | 28.17M | 37.16M | 24.34M | 14.23M |
| Gross Profit | 4.24M | 4.78M | 9.11M | 12.92M | 7.21M | 3.94M |
| EBITDA | -13.25M | -13.09M | -23.52M | -22.12M | -22.59M | -13.65M |
| Net Income | -16.89M | -16.56M | -22.09M | -28.75M | -26.47M | -15.98M |
Balance Sheet | ||||||
| Total Assets | 9.47M | 10.90M | 12.88M | 31.68M | 49.95M | 44.20M |
| Cash, Cash Equivalents and Short-Term Investments | 138.00K | 133.00K | 764.00K | 1.15M | 13.76M | 19.18M |
| Total Debt | 662.00K | 9.62M | 1.04M | 4.20M | 6.08M | 1.30T |
| Total Liabilities | 48.36M | 43.47M | 40.59M | 45.12M | 43.82M | 14.49M |
| Stockholders Equity | -38.89M | -32.56M | -27.71M | -13.44M | 6.13M | 29.71M |
Cash Flow | ||||||
| Free Cash Flow | -8.71M | -7.45M | -15.16M | -15.75M | -36.20M | -12.54M |
| Operating Cash Flow | -8.71M | -7.45M | -15.16M | -15.75M | -35.24M | -10.79M |
| Investing Cash Flow | 0 | 500.00K | 227.00K | 1.03M | 32.42M | 9.64M |
| Financing Cash Flow | 7.00M | 6.67M | 10.67M | 5.10M | 196 | 25.27M |
Marpai Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRAI, the sentiment is Neutral. The current price of 2.74 is below the 20-day moving average (MA) of 3.17, below the 50-day MA of 3.07, and above the 200-day MA of 1.34, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 43.42 is Neutral, neither overbought nor oversold. The STOCH value of 35.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MRAI.
Marpai Risk Analysis
Marpai disclosed 18 risk factors in its most recent earnings report. Marpai reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskMarpai Peers Comparison
Overall Rating
CLOV73Outperform
OSCR70Outperform
ALHC59Neutral- MRAI53Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| CLOV | 73Outperform | $2.37B | -110.12 | -5.38% | ― | 54.04% | 57.31% |
| OSCR | 70Outperform | $9.38B | 17.76 | 38.53% | ― | 42.82% | ― |
| ALHC | 59Neutral | $1.52B | 51.63 | 12.46% | ― | 35.87% | ― |
| MRAI | 53Neutral | $79.52M | -3.84 | 48.23% | ― | -29.73% | 11.01% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MRAI | Marpai, Inc. | 2.96 | 1.54 | 108.31% | |
| CLOV | Clover Health Investments Corp | 4.46 | 0.94 | 26.70% | |
| OSCR | Oscar Health, Inc. | 30.37 | 13.21 | 76.98% | |
| ALHC | Alignment Healthcare, Inc. | 7.27 | -9.82 | -57.46% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 11, 2026